The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review

Anderson, 2000, Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability, J. Affect. Disord., 58, 19, 10.1016/S0165-0327(99)00092-0

Andreoli, 2002, Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression, J. Clin. Psychiatry, 22, 393

Ascher, 1995, Bupropion: a review of its mechanism of antidepressant activity, J. Clin. Psychiatry, 56, 395

Bai, 2003, Chronic α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptor potentiator (LY451646) increases cell proliferation in adult rat hippocampus, Neuropharmacology, 44, 1013, 10.1016/S0028-3908(03)00104-7

Bartoszyk, 1997, EMD 68843, a serotonin reuptake inhibitor with presynaptic 5-HT1A receptor agonistic properties, Eur. J. Pharmacol., 464, 127

Belanoff, 2001, Rapid reversal of psychotic depression using mifepristone, J. Clin. Psychopharmacol., 21, 516, 10.1097/00004714-200110000-00009

Berman, 2000, Antidepressant effects of ketamine in depression, Biol. Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9

Blendy, 1990, Electroconvulsive shock differentially increases binding to α1 adrenergic receptor subtypes in discrete regions of rat brain, J. Neurosci., 10, 2580, 10.1523/JNEUROSCI.10-08-02580.1990

Blier, 2003, The pharmacology of putative early-onset antidepressant strategies, Eur. NeuroPsychopharmacol., 13, 57, 10.1016/S0924-977X(02)00173-6

Borsini, 2002, Pharmacology of flibanserin, CNS Drug Rev., 8, 117, 10.1111/j.1527-3458.2002.tb00219.x

Bymaster, 2003, New approaches to developing antidepressants by enhancing monoaminergic transmission, Expert Opin. Investig. Drugs, 12, 531, 10.1517/13543784.12.4.531

Cassano, 2002, Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study, Int. Clin. Psychopharmacol., 17, 27, 10.1097/00004850-200201000-00004

Cordi, 2001, Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties, J. Med. Chem., 44, 787, 10.1021/jm001040g

Corrigan, 2000, Comparison of pramipexole, fluoxetine, and placebo in patients with major depression, Depress. Anxiety, 11, 58, 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H

Crissman, 2002, Effects of antidepressants in rats trained to discriminative centrally administered isoproterenol, J. Pharmacol. Exp. Ther., 302, 606, 10.1124/jpet.102.034686

Cryan, 2002, Assessing antidepressant activity in rodents: recent developments and future needs, Trends Pharmacol. Sci., 23, 238, 10.1016/S0165-6147(02)02017-5

Davidson, 2003, The neural substrates of affective processing in depressed patients treated with venlafaxine, Am. J. Psychiatry, 160, 64, 10.1176/appi.ajp.160.1.64

Davis, 1997, Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression, Drugs, 53, 608, 10.2165/00003495-199753040-00006

Delgado, 2000, Depression: the case for monoamine deficiency, J. Clin. Psychiatry, 61, 7

Devoto, 2004, Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex, J. Neurochem., 88, 1003, 10.1046/j.1471-4159.2003.02239.x

Devoto, 2004, Mirtazapine-induced co-release of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex, Eur. J. Pharmacol., 487, 105, 10.1016/j.ejphar.2004.01.018

Di Matteo, 2003, Serotonin control of dopaminergic neurotransmission: focus on 5-HT2 receptors, Curr. Neuropharmacol., 1, 153, 10.2174/1570159033477189

Donati, 2003, G-protein signalling and the molecular basis of antidepressant action, Life Sci., 73, 1, 10.1016/S0024-3205(03)00249-2

Flügge, 2003, α2A and α2C-adrenoceptor regulation in the brain: α2A changes persist after chronic stress, Eur. J. Neurosci., 17, 917, 10.1046/j.1460-9568.2003.02510.x

Gobert, 1999, Modulation of dialysate levels of dopamine, noradrenaline, and 5-HT in frontal cortex of freely-moving rats by (−)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of β-adrenergic, 5-HT1A, and 5-HT1B receptors, Neuropsychopharmacology, 21, 268, 10.1016/S0893-133X(99)00035-4

Gold, 2002, Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states, Mol. Psychiatry, 7, 254, 10.1038/sj.mp.4001032

Greenberg, 2003, The economic burden of depression in the United States: how did it change between 1990 and 2000?, J. Clin. Psychiatry, 64, 1465, 10.4088/JCP.v64n1211

Grove, 2000, Positive modulators of the α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptor, Expert Opin. Ther. Pat., 10, 1539, 10.1517/13543776.10.10.1539

Gründer, G., Wetzel, H., Hammes, E., Benkert, O., Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology. 111, 123–126.

Guiard, 2004, Blockade of substance P (neurokinin1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice, J. Neurochem., 89, 54, 10.1046/j.1471-4159.2003.02304.x

Hammack, 2003, Corticotropin releasing hormone type 2 receptors in dorsal raphe nucleus mediate the behavioural consequences of stress, J. Neurosci., 23, 1019, 10.1523/JNEUROSCI.23-03-01019.2003

Hoyberg, 2002, Org 34517, a selective glucocortical receptor antagonist with potent antidepressant activity. First clinical results, Int. J. Neuropsychopharmacol., 5

Hong, 2003, Genomic approaches to depression, Curr. Pharmacogen., 1, 67, 10.2174/1570160033378295

Hudzik, 2003, Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist, J. Pharmacol. Exp. Ther., 304, 1072, 10.1124/jpet.102.045468

Jacobs, 2000, Adult brain neurogenesis and psychiatry: a novel theory of depression, Mol. Psychiatry, 5, 262, 10.1038/sj.mp.4000712

Joyce, 2001, Dopamine D3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs, Pharmacol. Ther., 90, 231, 10.1016/S0163-7258(01)00139-5

Kasper, 1995, Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data, Int. Clin. Psychopharmacol., 10, 25, 10.1097/00004850-199512004-00005

Kinney, 2000, The augmentation hypothesis for improvement of antidepressant therapy, Mol. Neurobiol., 21, 137, 10.1385/MN:21:3:137

Kitayama, 2003, Norepinephrine transporter splice variants and their interaction with substrates and blockers, Eur. J. Pharmacol., 479, 65, 10.1016/j.ejphar.2003.08.057

Léger, 2002, Neurokinin NK1- and NK3-immunoreactive neurones in serotonergic cell groups in the rat brain, Neurosci. Lett., 323, 146, 10.1016/S0304-3940(01)02543-5

Lehr, 2002, Potential antidepressant properties of pramipexole detected in locomotor and operant behavioural investigation in mice, Psychopharmacology, 163, 495, 10.1007/s00213-002-1199-7

Lejeune, 2002, The selective neurokinin (NK)1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study, Brain Res., 935, 134, 10.1016/S0006-8993(02)02476-9

Lerer, 2002, Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions, Int. J. Neuropsychopharmacol., 8, 255

Leysen, 2004, 5-HT2 receptors, Curr. Drug Targets, 3, 11

Li, 2003, Enhancement of antidepressant potency by a potentiator of α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptors, Cell. Mol. Neurobiol., 23, 419, 10.1023/A:1023648923447

Lôo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder. A placebo controlled dose range study, Int. Clin. Psychopharmacol., 17, 239, 10.1097/00004850-200209000-00004

Lucki, 1994, Antidepressant-like behavioral effects of serotonin receptor agonists, Neurosci. Biobehav. Rev., 18, 85, 10.1016/0149-7634(94)90039-6

Mackowiak, 2002, An α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptor potentiator modulates hippocampal expression of brain-derived neurotrophic factor, Neuropharmacology, 43, 1, 10.1016/S0028-3908(02)00066-7

Malberg, 2003, Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment, Neuropsychopharmacology, 28, 1562, 10.1038/sj.npp.1300234

Manji, 2003, Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression, Biol. Psychiatry, 53, 707, 10.1016/S0006-3223(03)00117-3

Maubach, 1999, Novel strategies for pharmacotherapy of depression, Curr. Opin. Chem. Biol., 3, 481, 10.1016/S1367-5931(99)80070-2

Maurice, 2001, The interaction between neuroactive steroids and the sigma1 receptors: function, behavioral consequences and therapeutic opportunities, Brain Res. Rev., 37, 116, 10.1016/S0165-0173(01)00112-6

Mayorga, 2001, Antidepressant-like behavioral effects in 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor mutant mice, J. Pharmacol. Exp. Ther., 298, 1101

McEwen, 2000, Effects of adverse experiences for brain structure and function, Biol. Psychiatry, 48, 721, 10.1016/S0006-3223(00)00964-1

Millan, 2003, The neurobiology and control of anxious states, Prog. Neurobiol., 70, 83, 10.1016/S0301-0082(03)00087-X

Millan, 1992, Targeting multiple serotonin receptors: 5-HT1A agonists/5-HT1C/2 antagonists as therapeutic agents, Drug News Perspect., 5, 397

Millan, 2000, Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2 and 5-HT2C receptors: a comparison with citalopram, Eur. J. Neurosci., 12, 1079, 10.1046/j.1460-9568.2000.00982.x

Millan, 2000, Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: a review, and relevance to the actions of antidepressant agents, J. Psychopharmacol., 14, 114, 10.1177/026988110001400202

Millan, 2001, S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine, J. Pharmacol. Exp. Ther., 298, 565

Millan, 2001, Selective blockade of neurokinin (NK)1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats, J. Neurochem., 76, 1949, 10.1046/j.1471-4159.2001.00211.x

Millan, 2003, The novel melatonin agonist, agomelatine (S20098), is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways, J. Pharmacol. Exp. Ther., 306, 954, 10.1124/jpet.103.051797

Millan, 2004, Anxiolytic properties of agomelatine, and antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade, Psychopharmacology, 10.1007/s00213-003-1770-x

Millan, 2004, S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison to ropinirole, J. Pharmacol. Exp. Ther., 309, 162

Mitchell, 2001, LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat, Eur. J. Pharmacol., 432, 19, 10.1016/S0014-2999(01)01469-8

Montgomery, 2002, Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction, J. Affect. Disord., 69, 119, 10.1016/S0165-0327(01)00313-5

Morcuende, 2003, Increased neurogenesis and BDNF in neurokinin−1 receptor gene knockout mice, Eur. J. Neurosci., 18, 1828, 10.1046/j.1460-9568.2003.02911.x

Nalepa, 2002, Repeated imipramine and electroconvulsive shock increase α1A-adrenoceptor mRNA level in rat prefrontal cortex, Eur. J. Pharmacol., 444, 151, 10.1016/S0014-2999(02)01660-6

Naranjo, 2001, The role of the brain reward system in depression, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 25, 781, 10.1016/S0278-5846(01)00156-7

Naughton, 2000, A review of the role of serotonin receptors in psychiatric disorders, Hum. Psychopharm. Clin. Exp., 15, 397, 10.1002/1099-1077(200008)15:6<397::AID-HUP212>3.0.CO;2-L

Nelson, 2004, 5-HT5 receptors, Curr. Drug Targets, 3, 53

Newton, 2002, Inhibition of cAMP or dynorphin in the nucleus accumbens produces an antidepressant-like effect, J. Neurosci., 24, 10883, 10.1523/JNEUROSCI.22-24-10883.2002

Nguyen, 2003, Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases, Prog. Neurobiol., 71, 401, 10.1016/j.pneurobio.2003.12.003

Nutt, 1996, α2-Adrenoceptors and depression, J. Psychopharmacol., 10, 35

O'Donnell, 2004, Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4), Trends Pharmacol. Sci., 25, 158, 10.1016/j.tips.2004.01.003

Ordway, 2003, Elevated agonist binding to α2-adrenoceptors in locus coeruleus in depression, Biol. Psychiatry, 53, 315, 10.1016/S0006-3223(02)01728-6

Pacher, 2001, Current trends in the development of new antidepressants, Curr. Med. Chem., 8, 89, 10.2174/0929867013373796

Padovan, 2004, Antidepressant-like effects of NMDA receptor antagonists injected into the dorsal hippocampus of rats, Pharmacol. Biochem. Behav., 77, 15, 10.1016/j.pbb.2003.09.015

Panocka, 2001, Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity, Peptides, 22, 1037, 10.1016/S0196-9781(01)00438-7

Payne, 2002, Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?, Biol. Psychiatry, 52, 921, 10.1016/S0006-3223(02)01676-1

Pei, 2003, Antidepressant drug treatment induces Arc gene expression in the rat brain, Neuroscience, 121, 975, 10.1016/S0306-4522(03)00504-9

Pei, 2004, Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex, Neuropharmacology, 46, 331, 10.1016/j.neuropharm.2003.09.017

Perez, 2001, Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors, J. Clin. Psychopharmacol., 21, 36, 10.1097/00004714-200102000-00008

Raffa, 1998, Possible roles of neurokinins in central nervous system development and neurodegenerative or other disorders, Neurosci. Biobehav. Rev., 22, 789, 10.1016/S0149-7634(97)00070-5

Reagan, 2004, Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine, PNAS, 101, 2179, 10.1073/pnas.0307294101

Reul, 2002, Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression, Curr. Opin. Pharmacol., 2, 23, 10.1016/S1471-4892(01)00117-5

Reus, 2001, Antiglucocorticoid drugs in the treatment of depression, Exp. Opin. Invest., 10, 1789, 10.1517/13543784.10.10.1789

Rogoz, 2002, Synergistic effect of uncompetitive N-methyl-d-aspartate receptor antagonists and antidepressant drugs in the forced swimming test in rats, Neuropharmacology, 42, 1024, 10.1016/S0028-3908(02)00055-2

Rollema, 1996, Comparison of the effects of CP-93,393 and buspirone on 5-HAT and NE release: microdialysis studies in the hippocampus of freely moving rats and guinea pigs, J. Neurochem., 66, S37

Roth, 2004, Magic shotguns vs. magic bullets: selectively non-selective drugs for mood disorders and schizophrenia, Nat. Rev., Drug Discov., 3, 353, 10.1038/nrd1346

Rupniak, 2002, Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists, Curr. Opin. Investig. Drugs, 3, 257

Ryckmans, 2002, Dual NK1 antagonists–serotonin reuptake inhibitors as antidepressants. SAR and activity of benzyloxyphenthyl1 piperazine derivatives, Bioorg. Med. Chem. Lett., 12, 3195, 10.1016/S0960-894X(02)00563-2

Sallinen, 1998, Genetic alteration of the α2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels, Mol. Psychiatry, 4, 443, 10.1038/sj.mp.4000543

Sanchez, 1999, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding, Cell. Mol. Neurobiol., 19, 467, 10.1023/A:1006986824213

Santarelli, 2003, Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants, Science, 301, 805, 10.1126/science.1083328

Schatzberg, 2002, Pharmacological principles of antidepressant efficacy, Hum. Psychopharmacol., 17, S17, 10.1002/hup.399

Schmitt, 1993, Further characterization of the long-term effect of RU24722 on tyrosine hydroxylase in the rat locus coeruleus, J. Neurochem., 61, 1423, 10.1111/j.1471-4159.1993.tb13636.x

Schramm, 2001, The α2A-adrenergic receptor plays a protective role in mouse models of depression and anxiety, J. Neurosci., 21, 4875, 10.1523/JNEUROSCI.21-13-04875.2001

Shelton, 2001, A novel augmentation strategy for treating resistant major depression, Am. J. Psychiatry, 158, 131, 10.1176/appi.ajp.158.1.131

Shirayama, 2002, BDNF produces antidepressant effects in behavioural models of depression, J. Neurosci., 22, 3251, 10.1523/JNEUROSCI.22-08-03251.2002

Shorter, 2003, Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease, Br. Med. J., 327, 158, 10.1136/bmj.327.7407.158

Skolnick, 2001, Current perspectives on the development of non-biogenic amine-based antidepressants, Pharmacol. Res., 43, 411, 10.1006/phrs.2000.0806

Sorbera, 1999, Robalzotan tartrate hydrate, Drugs Future, 24, 740, 10.1358/dof.1999.024.07.530723

Steinberg, 2001, Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function, J. Pharmacol. Exp. Ther., 299, 449

Stone, 2003, Emerging evidence for a central epinephrine-innervated α1-adrenergic system that regulates behavioral activation and is impaired in depression, Neuropsychopharmacology, 28, 1387, 10.1038/sj.npp.1300222

Svenningsson, 2002, Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac), Proc. Natl. Acad. Sci., 99, 3182, 10.1073/pnas.052712799

Tamminga, 2002, Developing novel treatments for mood disorders: accelerating discovery, Biol. Psychiatry, 52, 589, 10.1016/S0006-3223(02)01470-1

Thomas, 2004, 5-HT7 receptors, Curr. Drug Targets, 3, 81

Torres, 2003, Plasma membrane monoamine transporters: structure, regulation and function, Nat. Rev., Neurosci., 4, 13, 10.1038/nrn1008

Tottori, 2001, Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523, Neuropharmacology, 41, 976, 10.1016/S0028-3908(01)00147-2

Urani, 2002, The antidepressant-like effect induced by the sigma1 receptor agonist igmesine involves modulation of intracellular calcium mobilization, Psychopharmacology, 163, 26, 10.1007/s00213-002-1150-y

Van der Hart, 2002, Substance P antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis and hippocampal volume, Mol. Psychiatry, 7, 933, 10.1038/sj.mp.4001130

Vetulani, 2000, Antidepressants: past, present and future, Eur. J. Pharmacol., 405, 351, 10.1016/S0014-2999(00)00565-3

Vida, 1999, Precision and comparability of adverse event rates of newer antidepressants, J. Clin. Psychopharmacol., 19, 416, 10.1097/00004714-199910000-00005

Walker, 2003, Synthesis of serotonin by a second tryptophan hydroxylase isoform, Science, 299, 76, 10.1126/science.1078197

Wong, 2004, From monoamines to genomic targets: a paradigm shift for drug discovery in depression, Nat. Rev., Neurosci., 3, 136, 10.1038/nrd1303

Woolley, 2004, 5-HT6 receptors, Curr. Drug Targets, 3, 59

Ybema, 2003, Lack of anti-depressant efficacy of the selective 5-HT1A receptor antagonist NAD-299. Results from an 8 week placebo and paroxetine-controlled study, Eur. Neuropsychopharmacol., 13, S189, 10.1016/S0924-977X(03)91747-0

Zajecka, 2003, Treating depression to remission, J. Clin. Psychiatry, 64, 7

Zarate, 2003, Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders, Psychopharmacol. Bull., 36, 35

Zhang, 2002, Antidepressant-like profile and reduced sensitivity to Rolipram in mice deficient in the PDE4D phosphodiesterase enzyme, Neuropsychopharmacology, 27, 587

Zhang, 2003, Antagonism of the antidepressant-like effects of clenbuterol by central administration of β-adrenergic antagonists in rats, Psychopharmacology, 170, 102, 10.1007/s00213-003-1512-0

Zobel, 2000, Effects of the high-affinity corticotropin-releasing hormone receptor1 antagonist, R121919, in major depression: the first 20 patients treated, J. Psychiat. Res., 34, 181, 10.1016/S0022-3956(00)00016-9